BTSGU — BrightSpring Health Services, Inc. Tangible Equity Unit

Summary of BrightSpring Health Services, Inc. Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $3.6 billion, up 26% year-over-year.
• Pharmacy Solutions Revenue: $3.2 billion, a 25% increase.
• Provider Services Revenue: $442 million, growing 28%.
• Adjusted EBITDA: $190 million, a 45% increase, with a margin of 5.3%, up 70 basis points year-over-year.
• Cash Flow from Operations: $123 million, excluding Community Living divestiture.
• Leverage Ratio: 2.27x as of March 31, 2026, improved from 2.99x at year-end 2025.
• Adjusted EPS: $0.39.

2. Strategic Updates and Business Highlights

• BrightSpring remains a leader in home and community health services, focusing on high-quality care for complex patients.
• Successful integration of acquired Amedisys and LHC branches is expected to contribute approximately $30 million in EBITDA in the first year.
• Pharmacy Solutions showed strong growth in specialty and infusion services, with a focus on expanding geographic reach and enhancing operational efficiencies.
• Home Health services reported robust growth, with 49% revenue increase driven by market share gains and successful integration of acquired branches.
• The company is actively pursuing innovation in service delivery and operational processes, with ongoing investments in automation and technology.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected between $14.725 billion and $15.225 billion, reflecting 14.1% to 17.9% growth over 2025.
• Adjusted EBITDA Guidance: Projected between $795 million and $825 million, indicating 28.7% to 33.6% growth over the previous year.
• The company anticipates continued strong performance in both pharmacy and provider segments, supported by operational efficiencies and strategic initiatives.

4. Bad News, Challenges, or Points of Concern

• Impact from IRA: Home and Community Pharmacy revenue is expected to be negatively impacted by approximately $175 million due to the Inflation Reduction Act (IRA).
• Headwinds from Generic Conversions: Anticipated revenue headwinds of about $250 million from brand to generic conversions.
• Competitive Pressures: Concerns about PBMs pushing private label biosimilars and the potential impact on market share and pricing.
• Corporate Costs: Significant increase in corporate expenses, up approximately 40% sequentially, attributed to investments in IT and salesforce, raising concerns about ongoing operational efficiency.

5. Notable Q&A Insights

• Infusion Growth: The company reported double-digit growth in both acute and chronic specialty infusion segments, with ongoing efforts to expand market presence.
• Value-Based Care: BrightSpring is exploring new ACO programs to enhance value-based care offerings, aiming to reduce costs while improving patient outcomes.
• Market Share in Specialty: The company is gaining market share in specialty pharmacy, particularly in oncology, with a focus on exclusive drug agreements.
• Operational Efficiencies: Continued emphasis on operational improvements and AI applications to streamline processes and enhance margins.
• PBM Dynamics: Management expressed confidence in their current relationships with payers and PBMs, indicating no significant changes impacting their agreements or product offerings.

Overall, BrightSpring Health Services demonstrated strong financial performance in Q1 2026, with significant growth across its segments, while also navigating challenges related to regulatory impacts and competitive pressures. The company remains focused on strategic initiatives to drive future growth and operational efficiency.